Da LeukoScan ikke er blevet undersøgt hos patienter i alderen 21 år eller derunder, bør lægen omhyggeligt afveje fordele og risici ved brugen af LeukoScan, inden behandlingen gives til en patient i denne aldersgruppe.
Because LeukoScan has not been studied in patients aged 21 years or younger, doctors should carefully weigh the benefits and the risks of its use before administering it to a patient in this age group.